We are very excited to be part of an international consortium that has been awarded a Eurostars grant for the development of first-in-class treatment of metastatic cancer. ONA Therapeutics, Absolute Antibody and RIC received the grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Absolute Antibody will engineer the biologic into an optimized format and then recombinantly produce and purify the molecule for preclinical analysis.
Taking the lives of more than 9 million people globally each year, metastatic cancers are often unresponsive to existing cancer treatments, leaving a large unmet need. In order to tackle this important health problem, the newly established consortium – named LIPOLOGIC – will combine industry know-how in complementary areas of drug development: from target discovery, across molecule formatting and manufacturing, to lead selection and characterization. The initiative is funded by the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme.
Read the official announcement here to learn more about the project and the role of each partner company.
AUTM Virtual Annual Meeting
15-18th March 2021